Phase III Study of TAS-118 Plus Oxaliplatin Versus S-1 Plus Cisplatin in Patients With Advanced Gastric Cancer

NCT02322593 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

711

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastric Cancer

Interventions

DRUG: TAS-118 plus Oxaliplatin
DRUG: S-1 plus Cisplatin

Sponsor

Taiho Pharmaceutical Co., Ltd.

Collaborators

[object Object]